Objective: Human chorionic gonadotropin (hCG) is widely used in the management of hydatidiform mole and persistent trophoblastic disease (PTD). Predicting PTD after molar pregnancy might be beneficial since prophylactic chemotherapy reduces the incidence of PTD. Design: A retrospective study based on blood specimens collected in the Dutch Registry for Hydatidiform Moles. A group of 165 patients with complete moles (of which 43 had PTD) and 39 patients with partial moles (of which 7 had PTD) were compared with 27 pregnant women with uneventful pregnancy. Methods: Serum samples from patients with hydatidiform mole with or without PTD were assayed using specific (radio)immunoassays for free a-subunit (hCGa), free b-subunit (hCGb) and 'total' hCG (hCG þ hCGb). In addition, we calculated the ratios hCGa/hCG þ hCGb, hCGb/hCG þ hCGb, and hCGa/hCGb. Specificity and sensitivity were calculated and paired in receiver-operating characteristic (ROC) curve analysis, resulting in areas under the curves (AUCs). Results: hCGb, hCGb/hCG þ hCGb and hCGa/hCGb show AUCs ranging between 0.922 and 0.999 and, therefore, are excellent diagnostic tests to distinguish complete and partial moles from normal pregnancy. To distinguish partial from complete moles the analytes hCGb, hCG þ hCGb and the ratio hCGa/hCGb have AUCs between 0.7 and 0.8. Although hCGa, hCGb and hCG þ hCGb concentrations are significantly elevated in patients who will develop PTD compared with patients with spontaneous regression after evacuation of their moles, in predicting PTD, these analytes and parameters have AUCs ,0.7. Conclusions: Distinction between hydatidiform mole and normal pregnancy is best shown by a single blood specimen with hCGb, but hCGb/hCG þ hCGb and hCGa/hCGb are also excellent diagnostic parameters. To predict PTD, hCGa, hCGb, hCG þ hCGb and hCGa/hCGb are moderately accurate tests, although they are not accurate enough to justify prophylactic chemotherapy treatment for prevention of PTD.
Introduction
Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced by trophoblastic tissue and therefore is a key marker in pregnancy and gestational trophoblastic disease (GTD) (1) . A variety of pathological types of trophoblast are included in GTD comprising villous malformations of the trophoblast: hydatidiform mole, subdivided into complete and partial hydatidiform moles, and non-villous malformations of which choriocarcinoma is the most frequent (2) . Genetically, complete moles are diploid (46 XX or XY) which is the result of an 'empty' oocyte (after degeneration of the nucleus) being fertilized by one haploid sperm, followed by duplication of its chromosome, or fertilization of an empty egg by two spermatozoa (3) . The syndrome of partial (incomplete) mole has an ascertainable fetus (alive or dead) and a triploid karyotype (69 XXX or XXY) after fertilization of a normal ovum by two spermatozoa (3) . Incidence of hydatiform mole is highest in South-East Asia, Indonesia, India and Turkey with rates ranging from 2 to 12 per 1000 pregnancies. In North America and Europe, incidence is lower: 0.5 to 1 per 1000 pregnancies. Interestingly, significant reductions in the incidence of hydatidiform mole have recently been reported in Korea, Japan and Taiwan to levels comparable to those in North America and Europe (4) . In persistent trophoblastic disease (PTD), trophoblastic activity remains after evacuation of the hydatidiform mole as shown by subsequent unaltered high or even rising hCG concentrations in blood. The reported frequency of PTD is 20% in complete hydatidiform mole (5) and 0.5 to 9.9% in partial hydatidiform mole (6 -9) . In order to prevent complications from metastatic disease, PTD needs to be treated. Prophylactic chemotherapy (started immediately after evacuation of the mole) reduces the incidence of PTD to 4-12% (10, 11) . Because of the large proportion of patients who will show spontaneous remission of molar pregnancy after evacuation and because of the side effects of chemotherapy, clinicians are reluctant to use prophylactic chemotherapy. It would therefore be helpful to identify patients at risk for developing PTD. hCG is composed of two non-covalently bound a-and b-subunits. The a-subunit of hCG comprises 92 amino acids and is identical to the a-subunit of the pituitary glycoprotein hormones follicle-stimulating hormone (FSH), thyrotropin (TSH) and luteinizing hormone (LH). The b-subunit is composed of 145 amino acids, which distinguish hCG from these other glycoproteins. In addition to intact hCG, free hCG a-subunit, free hCG b-subunit, and the hCG b-subunit core fragment are present in blood. Since most hCG radioimmunoassays detect both intact hCG and free hCGb, these tests are designated 'total hCG' or 'hCG þ hCGb' assays. In normal pregnancy, concentrations of intact hCG, hCG þ hCGb and hCGb in blood double approximately every 2 days to reach a peak at 8 to 10 weeks of gestation. From week 10 to 20, these concentrations decline to levels comparable to those in early first trimester and from 20 weeks on they remain constantly low (12) . In contrast, hCGa concentrations in blood increase steadily until the end of pregnancy (13) . The production of subunits of hCG is under stringent physiological control in normal pregnancy, and is reported to be different in pathological states such as hydatidiform mole (14 -16) , although the literature data are not unequivocal. In particular, the concentration of hCGb and the ratio of hCGb to total hCGb is reported to be increased in molar as compared with normal pregnancy (17) . Some studies, using a limited number of patients, reported that an increased ratio of hCGb to total hCGb identifies patients with molar pregnancy who are at risk of developing persistent disease (18 -20) , although other investigators did not report such an association (14) .
The present retrospective study includes measurement of hCGa, hCGb and hCG þ hCGb and calculates the ratios of hCGa/hCG þ hCGb, hCGb/hCG þ hCGb and hCGa/hCGb in blood taken before evacuation from 203 patients with hydatidiform mole of which 43 developed PTD. The aim of this study is to evaluate the clinical utility of the six hCG parameters by receiver-operating characteristic (ROC) curve analysis to distinguish normal pregnancy from hydatidiform mole, partial from complete mole, and to predict the occurrence of PTD.
Materials and methods

Patients
In The Netherlands, patients with hydatidiform mole can be registered, after informed consent, at the Dutch Central Registry for Hydatidiform Moles residing at the Radboud University Nijmegen Medical Centre (RUNMC). We have included 1630 patients in this database. We excluded all patients with a histological diagnosis of choriocarcinoma. In 692 registered patients with hydatidiform mole, hCG in blood was analyzed in our department at the RUNMC. After collection, blood samples were centrifuged and serum was sent to our institute and kept at 2 20 8C until assayed. Of these 692 patients, 430 had to be excluded since no blood specimen was taken prior to evacuation. Another 58 patients were excluded to match the gestational age in the control group. This led to the selection of 204 patients (mean age 27.9 years, range 16 to 54 years). Of those 204 patients, 129 had a complete hydatidiform mole with normal serum hCG regression (Group 1), as derived from a normal regression curve constructed by Yedema et al. (21) . Another 36 patients with a complete mole developed PTD after evacuation (Group 2) while 32 patients had a partial mole with normal hCG regression (Group 3) whereas 7 patients with a partial hydatidiform mole developed PTD after evacuation (Group 4). The pathology institution of the Dutch Central Registry reviewed the histology of all patients with a hydatidiform mole. The control group comprised 27 women (mean age 28.2 years, range 23 to 39 years) with uneventful pregnancies, whose blood was collected on a weekly basis between 7 and 16 weeks of gestation except in weeks 13 and 15.
Immunoassays
All the measurements of 'total' hCG (i.e. intact hCG and free b-subunit, hCG þ hCGb) or its free a-or b-subunit in serum were performed with sensitive and specific radioimmunoassays (RIAs) that have been developed in our laboratory. The RIAs of hCG þ hCGb and hCGb have been described previously (22) , while the hCGa RIA was developed recently. Polyclonal anti-rabbit antisera were used in the RIAs of hCG þ hCGb and hCGa, and a monoclonal antibody (23) in the RIA for hCGb. A highly purified hCG b-subunit preparation labeled with iodine-125 (NaI 125 , Amersham plc, Amersham, Bucks, UK) was employed as a tracer in the RIAs of hCG þ hCGb and hCGb, while the RIA of hCGa used I 125 -labeled hCG asubunit as a tracer. The RIAs were calibrated with the third International Standard (IS) Preparations for intact hCG, hCG a-subunit or hCG b-subunit (WHO third IS hCG 75/537, hCGa 75/569 or hCGb 75/551 respectively, all obtained from the National Institute for Biological Standards, Potters Bar, Herts, UK). Conversion factors are as follows: hCGa: 1 mg/l is 0.0714 nmol/l and equivalent to 1 IU/l; hCGb: 1 mg/l is 0.0426 nmol/l and equivalent to 1 IU/l; hCG: 1 mg/l is 0.0267 nmol/l and equivalent to 9.29 IU/l. The measuring ranges of the assays were 0.027-2.14 nmol/l (1-80 mg/l equivalent to 9.29-743 IU/l) for hCG þ hCGb, 0.0036-0.43 nmol/l (0.05-6.0 IU/l or mg/l) for hCGa, and 0.0033-0.107 nmol/l (0.078-2.50 IU/l or mg/l) for hCGb. All the RIAs applied the same assay protocol. In brief, the procedure comprised the following steps. To increase the sensitivity of the RIAs, the mixtures of standard material or serum specimen together with the antiserum were incubated for 18 h at 20 8C, and after addition of labeled analyte this was followed by a second incubation (6 h at 20 8C). Antibody-bound and free analyte were separated by applying second antibody donkey anti-rabbit IgG coupled to cellulose (Sac-Cel, The Wellcome Foundation Ltd, Dartford, Kent, UK) in the case of the hCG þ hCGb and hCGa RIAs, and by donkey anti-mouse IgG coupled to cellulose in the free hCGb RIA. The RIA developed for hCGa cross-reacted 100% (on a molar basis at 50% displacement) with the a-subunits of LH, FSH and TSH, and 2%, 3.6%, 13% and 17% with the WHO International Reference Preparations (IRP) of native hCG, TSH, LH and FSH respectively.
Intact hCG and the free hCG b-subunit are abundantly present in serum samples from normal or mole pregnancies (unlike LH and FSH which are both suppressed during pregnancy while TSH concentrations are very low). For this reason, it was necessary to conduct an affinity chromatography procedure to eliminate intact hCG and free hCG b-subunit from each serum sample prior to determining its free hCG a-subunit concentration by this RIA. Thus, 100 ml serum were transferred to a HiTrap N-hydroxy-succinimide (NHS)-activated column (Pharmacia, Uppsala, Sweden) coupled to a polyclonal antiserum against free hCG bsubunit raised in rabbit, and the column effluent was checked by RIA for absence of the intact hCG and free hCG b-subunit present in the serum sample prior to chromatography. Next, the free hCG a-subunit concentrations were determined with the hCGa RIA. The free hCG b-subunit RIA showed a cross-reactivity with intact hCG of 0.35% (on a mass basis, equivalent to 0.55% on a molar basis) as tested with the WHO third IS 75/537 of hCG, 1.1% on a molar basis with nicked hCG (hCGn, WHO 99/642 Reference Reagent) and 0.4% with hCGbn (WHO 99/692 Reference Reagent) while the hCG þ hCGb RIA cross-reacted 100% on a molar basis with intact hCG and 1000% with hCG b-subunit, and 228% with hCGn and 507% with hCGbn (which is of minor practical importance because these nicked forms of hCG mainly occur in urine). The 95th percentile of the reference interval of healthy non-pregnant controls for the hCG þ hCGb assay was established at 0.053 nmol/l (2 mg/l or 18.6 IU/l of the WHO third IS hCG 75/537) (22) , 0.286 nmol/l (4.0 mg/l or IU/l of the WHO third IS hCGa 75/569) with the hCGa RIA, and 0.0085 nmol/l (0.20 mg/l or IU/l of the WHO third IS hCGb 75/551) with the hCGb RIA (24) . The intraand interassay coefficients of variation (CV w , CV b ) for means of duplicate measurements for two serum pools (mean: 0.267 nmol/l (10 mg/l or 93 IU/l) and 1.50 nmol/l (56 mg/l or 520 IU/l) were 7.3% and 12% for the hCG þ hCGb RIA, 3.3% -5.6% (CV w ) and 7.2% -8.4% (CV b ) with two serum pools (mean: 0.510 nmol/l (7.1 mg/l or IU/l) and 3.07 nmol/l (43 mg/l or IU/l)) in the case of the hCGa RIA, and 5.2% -5.8% (CV w ) and 9.5% -9.9% (CV b ) with two serum pools (mean: 0.014 nmol/l (0.33 mg/l or IU/l) and 0.041 nmol/l (0.96 mg/l or IU/l)) in the hCGb RIA.
Statistics
Calculation of reference values for normal pregnancy To construct reference values for normal pregnancy, we collected blood samples in our control group on a weekly basis from week 7 to 16 of gestational age except in weeks 13 and 15. We determined the longitudinal patterns ('response curve') of each experimentally determined hCG analyte (hCG þ hCGb, hCGa and hCGb, all expressed in nmol/l), as well as for the calculated molar ratios of hCG a-and b-subunits to hCG þ hCGb (hCGa/hCG þ hCGb and hCGb/hCG þ hCGb) and the ratio of hCGa to hCGb (hCGa/hCGb). In order to obtain normal Gaussian distributed data for the control group consisting of 27 pregnant women, we performed log transformations of all the determined hCGa concentrations (nmol/l) and calculated the molar ratio of hCGa/hCGb, while we performed square root transformation of the serum concentrations of hCGb (nmol/l), hCG þ hCGb (nmol/l) and its calculated molar ratio. Next, by subsequent pooling (over the weeks) of variances (25), we calculated P5, P50, and P95 for these transformed data (i.e. mean(log or square root)^1.645 S.E.(log or square root)) to become, after back transformation, the reference values (the 5th, 50th, and 95th percentiles, P5, P50, P95) separately for each week of the gestational period for the three analytes and the three molar ratios.
Statistical comparison of pregnancy controls with molar pregnancy subsets Each individual log-or square root-transformed hCG serum analyte or parameter from the 27 control pregnancies was expressed as a multiple of the median (MoM) for each gestational week. Because the longitudinal patterns for each individual patient revealed rather constant MoMs along the gestational period studied, we could calculate the mean MoM (mMoM) for each patient over the entire pregnancy period studied -weeks 7 to 16. From these mMoMs for each patient we calculated the 'grand' mMoM^S.E. Next, we calculated the MoMs for each of the available individual log-or square root-transformed hCG serum analytes of all the molar pregnancies. This was done for each mole by dividing the measured log-or square root-transformed blood concentration (or calculated ratios) of analyte or molar ratio by the corresponding P50 value of the control pregnancies as calculated and matched for the corresponding gestational week. Statistical significance of differences was tested with the Mann-Whitney U-test between the mean MoMs of all control pregnancies (the 'grand' mMoM) versus the calculated mean MoM of all molar pregnancies or versus the various subsets of moles (complete moles, partial moles), as well as between complete versus partial moles, or the presence or absence of PTD in the case of molar pregnancies. The calculated MoM values of all six hCG analytes and parameters of control and study groups were utilized to construct ROC curves and to calculate areas under the curve (AUC) for assessment of diagnostic accuracy of the test. All calculations were conducted with SPSS (version 12.0) for Microsoft Windows XP (SPSS, Chicago, IL, USA). ROC curves represent the full spectrum of possible sensitivity -specificity pairs for a test in a clinical application (26) . Usually, it is assumed that the study group has higher values of the tested parameters than the control group, resulting in an AUC between 0.5 and 1.0. Conversely, if results are lower in the study group than in the control group, an AUC between 0.0 and 0.5 is found (27) but this can easily be circumvented by reversing the state variable of the control and study group.
Results
Serum hCG parameters in hydatidiform molar pregnancy
Median serum hCGa concentrations increased steadily in the control pregnancies from 1.79 nmol/l (25 IU/l) at 7 weeks of gestation to 11.4 nmol/l (160 IU/l) at 16 weeks of gestation. Serum hCGb and hCGþhCGb concentrations were 0.248 nmol/l (5.8 IU/l) and 37.6 nmol/l (13 100 IU/l) respectively at week 7, showed a peak at 8-9 weeks of gestation (0.417 nmol/l (9.8 IU/l) and 59.6 nmol/l (21 000 IU/l) respectively) and then subsequently decreased to 0.032 nmol/l (0.75 IU/l) and 18.7 nmol/l (6500 IU/l) respectively at week 16 of gestation. Fig. 1 shows the serum concentrations of hCGa, hCGb, hCG þ hCGb and its calculated ratios (hCGa/hCG þ hCGb, hCGb/hCG þ hCGb and hCGa/hCGb) in complete and partial moles with or without PTD compared with the values in normal pregnancy between weeks 7 and 16 of gestation. In many molar pregnancies, hCGa concentrations in serum (Fig. 1A) are below the P50 levels of normal pregnancy. The hCGa/hCG þ hCGb ratio in the majority of molar pregnancies is below P5 (Fig. 1D) while almost all hCGa/hCGb ratios are below P5 of normal pregnancy (Fig. 1F) . In contrast to this, hCGb and hCG þ hCGb concentrations, and the ratio hCGb/hCG þ hCGb are mostly above the corresponding P95 levels of normal pregnancy (Fig. 1B, C and E) .
Comparison of serum hCG analytes and parameters in hydatidiform molar vs normal pregnancy
For each of the six hCG analytes and parameters investigated, we calculated the mean MoM (mMoM) values and their standard errors (S.E.) for the total and the individual groups of complete and partial molar pregnancy as compared with normal pregnancy (Table 1 ). This table also shows the comparisons between complete and partial moles, as well as all moles (complete and partial) without vs all moles with PTD.
The mean MoMs calculated for the concentrations of hCGb, hCG þ hCGb and the ratio hCGb/hCG þ hCGb were significantly higher in all molar pregnancies as well as in the complete molar pregnancy group compared with values in normal pregnancies (Table  1A and B). Comparable differences were also observed in the case of partial molar vs normal pregnancy except for hCG þ hCGb value, which was not significantly different (Table 1C) . The mMoMs for the ratios of hCGa/hCG þ hCGb and hCGa/hCGb in the all moles group and in its two subset groups were significantly lower than in normal pregnancy (Table 1A -C). The increase of the mMoMs observed for the group of all molar pregnancies (Table 1A) , as well as for the subsets of complete (Table 1B) or partial (Table 1C ) moles was highest in the case of hCGb, followed by the ratio of hCGb/hCG þ hCGb (Table 1A -C). The decrease of the mMoMs was highest in the case of the ratio of hCGa/hCG þ hCGb (Table 1A -C).
Comparison of serum hCG parameters in groups of hydatidiform molar pregnancy
The comparison between the complete and the partial molar pregnancies (Table 1D) showed that the mMoMs of both hCGa and the ratio of hCGb/hCG þ hCGb were not different, whereas the mMoMs for hCGb and hCG þ hCGb in the partial moles were significantly lower than in the complete molar pregnancies (P , 0.001). In contrast to this, the mMoM of the ratios of hCGa/hCG þ hCGb and hCGa/hCGb in partial moles were significantly higher than those of complete molar pregnancy (Table 1D ). In the case of all molar pregnancies with PTD as compared with all molar pregnancies without PTD, the three calculated ratios (hCGa/hCG þ hCGb, hCGb/hCG þ hCGb and hCGa/hCGb) were not significantly different, whereas the mMoM of all measured hCG analytes (hCGa, hCGb and hCG þ hCGb) were significantly higher in those cases where women developed PTD as compared with those who did not (Table 1E) .
Diagnostic accuracy
We established diagnostic accuracy by calculating specificity and sensitivity for the comparisons already presented in Table 1 . Based on these data we constructed the corresponding ROC curves for each of the three hCG analytes determined in blood specimens collected prior to evacuation as well as for the three ratios derived from these measurements (Fig. 2) . We then calculated the corresponding AUCs for the six hCG analytes and parameters ( Table 2 ). The ROC curves of all Figure 1 hCGa, hCGb, hCG þ hCGb, hCGa/hCG þ hCGb, hCGb/hCG þ hCGb and hCGa/hCGb in partial or complete mole with or without persistent trophoblastic disease compared with normal pregnancy (n ¼ 27). The two solid lines represent the 5th and the 95th percentile, whereas the dotted line represents the 50th percentile of normal pregnancy. Group 1(j), complete mole without PTD (n ¼ 129,); Group 2(X), complete mole with PTD (n ¼ 36,); Group 3(K), partial mole without PTD (n ¼ 32,); Group 4(O), partial mole with PTD (n ¼ 7,). The ratios of hCGa/hCG þ hCGb, hCGb/hCG þ hCGb and hCGa/hCGb are given in mol/mol, %.
hCG and hydatidiform mole 569 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005) 153 www.eje-online.org molar pregnancies ( Fig. 2A) vs normal pregnancy show AUCs ranging between 0.856 and 0.987 for all hCG analytes and parameters except for hCGa whose AUC was 0.618. hCGa/hCGb, hCGb/hCG þ hCGb and hCGb showed sensitivities of, respectively, 79%, 93%, and 95%, all at 100% specificity. We also found that hCG þ hCGb and hCGa/hCG þ hCGb displayed sensitivities of 82% and 85% at 90% specificity.
In the case of hCG þ hCGb and hCGa/hCG þ hCGb the subset of complete moles (Table 2B , Fig. 2B ) revealed higher AUCs (0.911 and 0.932) and the subset of partial moles revealed lower AUCs (0.621 and 0.788) (Table 2C , Fig. 2C ) as compared with all molar pregnancies vs normal pregnancy (AUCs of 0.856 and 0.902) (Table 2A , Fig. 2A ). Both in complete and partial hydatidiform mole, hCGb, hCGb/hCG þ hCGb and hCGa/hCGb were excellent diagnostic tests with AUCs ranging between 0.922 and 0.999 to distinguish these subsets from normal pregnancy (Table  2B ,C, Fig. 2B,C) . In the comparison of complete vs partial moles, five out of six hCG analytes and parameters tested (i.e. hCGb, hCG þ hCGb, hCGa/hCG þ hCGb, hCGb/hCG þ hCGb and hCGa/hCGb) showed AUCs ranging between 0.602 and 0.797, while hCGa showed an AUC of 0.549 (Table 2D, Fig. 2D ). In the comparison of moles without or with PTD, hCGa, hCGb, hCG þ hCGb and hCGa/hCGb showed AUCs ranging between 0.591 and 0.698, whereas the other two parameters revealed even lower AUCs (hCGb/hCG þ hCGb: 0.520, and hCGa/hCG þ hCGb: 0.568) (Table 2E , Fig. 2E ).
Discussion
The aim of our retrospective study was to explore the significance of six hCG analytes and parameters to distinguish hydatidiform mole from normal pregnancy, to distinguish complete from partial mole, and to assess whether any of these analytes and parameters is able Table 1 Mean multiple of the median (mMoMs)* for six hCG analytes and parameters compared in subsets of moles vs normal pregnancy, complete vs partial moles and in moles without vs with persistent trophoblastic disease (PTD) (first column represents number of controls in A, B and C and number of patients in D and E).
Parameter
Controls/Patients (n) mMoM to predict PTD. Specificity and sensitivity of all six hCG analytes and parameters in the various subsets of patient groups were explored in ROC curve analysis and the various AUCs thereof were compared for diagnostic accuracy. To distinguish hydatidiform molar from normal pregnancy, hCGb, hCGb/hCG þ hCGb and hCGa/hCGb proved to be excellent diagnostic tests with AUCs . 0.9 in the all moles group as well as in its mole subsets. The comparison of the group of all moles vs normal pregnancy showed AUCs of 0.856 with hCG þ hCGb and 0.902 for the ratio hCGa/hCG þ hCGb. The diagnostic accuracy of free hCGa was less with AUCs of 0.6 in the case of all the comparisons of moles with normal pregnancy. To distinguish complete from partial moles, five out of the six analytes and parameters tested (i.e. hCGb, hCG þ hCGb, hCGa/hCG þ hCGb, hCGb/hCG þ hCG and hCGa/hCGb) were found to have AUCs in the range of 0.6 to 0.8, whereas hCGa showed an even lower AUC of 0.549. To predict PTD after evacuation of a hydatidiform mole, we found hCGa, hCGb, hCG þ hCGb and hCGa/hCGb having AUCs in the range of 0.6 to 0.7. The other two parameters proved to have even lower AUCs (between 0.5 and 0.6). Our finding that the values of hCGb, hCG þ hCGb, and the ratio of hCGb/hCG þ hCGb in blood withdrawn prior to evacuation are significantly higher, and the ratios of hCGa/hCG þ hCGb and hCGa/hCGb are significantly lower in patients with hydatidiform mole as compared with normal pregnancy is in accordance with an earlier report which included only 5 patients with a hydatidiform mole (15) . Other studies with limited numbers of patients with hydatidiform mole, also showed that hCGb concentration (17) and the ratio hCGb/hCG þ hCGb (17, 19) were significantly higher while hCGa concentrations were not different in hydatidiform mole (17) . Berkowitz et al. (14) reported significantly higher concentrations of hCGa, hCGb, percentage hCGa and percentage hCGb (i.e. the free subunit to total subunit ratios), and no effect on the hCGb/hCGa ratio in partial moles (n ¼ 8) compared with normal pregnancy. Our data on hCGa/hCG þ hCGb and hCGa/hCGb ratios are not in line with that study as we found a significant decrease in these levels. Interestingly, in the case of the complete mole subgroup comprising more patients (n ¼ 20), the same authors reported significantly lower levels of the hCGa to intact hCG ratio and significantly higher concentrations of the hCGb/hCGa which is in line with our data. It has to be noted that Berkowitz et al. (14) used intact hCG to calculate the ratios of free a and free b to hCG, whereas we measured total hCG immunoreactivity, which included intact hCG as well as free hCGb-subunit. Evidently, the marked increased free PTD) (36) . Another potentially interesting parameter is hyperglycosylated hCG which was found to rise from 25% to 80% of total serum hCG when patients with persistent low levels of hCG developed gestational trophoblastic neoplasm (37) . The clinical value of this test in predicting PTD after hydatidiform mole remains to be elucidated. In summary, our study based on a large patient sample showed that hCGb in serum, and the ratios of hCGb/hCG þ hCGb and hCGa/hCGb are excellent diagnostic tests and parameters to make the distinction biochemically between hydatidiform mole and normal pregnancy at the 100% specificity level with more than 90% sensitivity. For practical use, the hCGb assay is recommended. The distinction between complete and partial hydatidiform mole cannot reliably be made with any of the tested analytes or parameters because diagnostic accuracy of these tests is at best qualified as moderately applicable. Finally, we found that although hCGa, hCGb and hCG þ hCGb concentrations are significantly elevated in the case of PTD, none of the six investigated hCG parameters had adequate diagnostic accuracy to permit the clinician to advise patients to undertake prophylactic chemotherapy after evacuation of a hydatidiform mole.
